MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ficker, E.
Right arrow Articles by Brown, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ficker, E.
Right arrow Articles by Brown, A. M.

Vol. 60, Issue 6, 1343-1348, December 2001

Molecular Determinants of Inactivation and Dofetilide Block in ether a-go-go (EAG) Channels and EAG-Related K+ Channels

Eckhard Ficker, Wolfgang Jarolimek,1 and Arthur M. Brown

Rammelkamp Center for Education and Research, MetroHealth Campus, Case Western Reserve University, School of Medicine, Cleveland, Ohio (E.F., A.M.B.); and I. Physiologisches Institut, Universitaet Heidelberg, Heidelberg, Germany (W.J.)

The major subunit of the cardiac delayed rectifier current IKr is encoded by the human ether a-go-go related gene (HERG). HERG/IKr channels are blocked selectively by class III antiarrhythmic methanesulfonanilide drugs such as dofetilide. The binding site for methanesulfonanilides is believed to be similar for nonantiarrhythmic drugs such as antihistamines, antibiotics, and antipsychotics. To gain further insight into the binding site, we examined the minimal structural changes necessary to transform low-affinity binding of dofetilide by the related bovine ether a-go-go channel bEAG to high-affinity binding of HERG. Previously, it was shown that high-affinity binding in HERG required intact C-type inactivation; the bovine ether a-go-go K+ channel (bEAG), unlike HERG, is noninactivating. Therefore, we introduced C-type inactivation into noninactivating bEAG using site-directed mutagenesis. Two point mutations in the pore region, T432S and A443S, were sufficient to produce C-type inactivation. Low concentrations of dofetilide produced block of bEAG T432S/A443S; unlike HERG, block was almost irreversible. Substitution of an additional amino acid in transmembrane domain S6 made the block reversible. Dofetilide blocked the triply mutated bEAG T432S/A443S/A453S with an IC50 value of 1.1 µM. The blocking potency was 30-fold greater than bEAG WT and about one third that of HERG WT. We conclude that high affinity methanesulfonanilide binding to HERG channels is strongly dependent on C-type inactivation.


1 Present address: Merck Sharp and Dohme Research Laboratories, Neuroscience Research Center, Harlow, Essex, UK.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Physiol.Home page
S. Z. Stepanovic, F. Potet, C. I. Petersen, J. A. Smith, J. Meiler, J. R. Balser, and S. Kupershmidt
The evolutionarily conserved residue A653 plays a key role in HERG channel closing
J. Physiol., June 1, 2009; 587(11): 2555 - 2566.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. J. Perrin, P. W. Kuchel, T. J. Campbell, and J. I. Vandenberg
Drug Binding to the Inactivated State Is Necessary but Not Sufficient for High-Affinity Binding to Human Ether-a-go-go-Related Gene Channels
Mol. Pharmacol., November 1, 2008; 74(5): 1443 - 1452.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
S. L. Wynia-Smith, A. L. Gillian-Daniel, K. A. Satyshur, and G. A. Robertson
hERG Gating Microdomains Defined by S6 Mutagenesis and Molecular Modeling
J. Gen. Physiol., October 27, 2008; 132(5): 507 - 520.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
H. Sale, J. Wang, T. J. O'Hara, D. J. Tester, P. Phartiyal, J.-Q. He, Y. Rudy, M. J. Ackerman, and G. A. Robertson
Physiological Properties of hERG 1a/1b Heteromeric Currents and a hERG 1b-Specific Mutation Associated With Long-QT Syndrome
Circ. Res., September 26, 2008; 103(7): e81 - e95.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. C. Hancox and A. F. James
Refining Insights into High-Affinity Drug Binding to the Human Ether-a-go-go-Related Gene Potassium Channel
Mol. Pharmacol., June 1, 2008; 73(6): 1592 - 1595.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
C. E. Clarke, A. P. Hill, J. Zhao, M. Kondo, R. N. Subbiah, T. J. Campbell, and J. I. Vandenberg
Effect of S5P {alpha}-helix charge mutants on inactivation of hERG K+ channels
J. Physiol., June 1, 2006; 573(2): 291 - 304.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Guo, H. Gang, and S. Zhang
Molecular Determinants of Cocaine Block of Human Ether-a-go-go-Related Gene Potassium Channels
J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 865 - 874.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Perry, P. J. Stansfeld, J. Leaney, C. Wood, M. J. de Groot, D. Leishman, M. J. Sutcliffe, and J. S. Mitcheson
Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs
Mol. Pharmacol., February 1, 2006; 69(2): 509 - 519.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
D. Fernandez, A. Ghanta, K. I Kinard, and M. C Sanguinetti
Molecular mapping of a site for Cd2+-induced modification of human ether-a-go-go-related gene (hERG) channel activation
J. Physiol., September 15, 2005; 567(3): 737 - 755.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
A. Dorn, F. Hermann, A. Ebneth, H. Bothmann, G. Trube, K. Christensen, and C. Apfel
Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition
J Biomol Screen, June 1, 2005; 10(4): 339 - 347.
[Abstract] [PDF]


Home page
JGPHome page
R. E. Garcia-Ferreiro, D. Kerschensteiner, F. Major, F. Monje, W. Stuhmer, and L. A. Pardo
Mechanism of Block of hEag1 K+ Channels by Imipramine and Astemizole
J. Gen. Physiol., September 27, 2004; 124(4): 301 - 317.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Gessner, M. Zacharias, S. Bechstedt, R. Schonherr, and S. H. Heinemann
Molecular Determinants for High-Affinity Block of Human EAG Potassium Channels by Antiarrhythmic Agents
Mol. Pharmacol., May 1, 2004; 65(5): 1120 - 1129.
[Abstract] [Full Text]


Home page
J. Physiol.Home page
G. C. L. Bett and R. L. Rasmusson
Inactivation and recovery in Kv1.4 K+ channels: lipophilic interactions at the intracellular mouth of the pore
J. Physiol., April 1, 2004; 556(1): 109 - 120.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon
Pharmacology of cardiac potassium channels
Cardiovasc Res, April 1, 2004; 62(1): 9 - 33.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Seebohm, J. Chen, N. Strutz, C. Culberson, C. Lerche, and M. C. Sanguinetti
Molecular Determinants of KCNQ1 Channel Block by a Benzodiazepine
Mol. Pharmacol., July 1, 2003; 64(1): 70 - 77.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
F. M. Mullins, S. Z. Stepanovic, R. R. Desai, A. L. George Jr., and J. R. Balser
Extracellular Sodium Interacts with the HERG Channel at an Outer Pore Site
J. Gen. Physiol., September 30, 2002; 120(4): 517 - 537.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Chen, G. Seebohm, and M. C. Sanguinetti
Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels
PNAS, September 17, 2002; 99(19): 12461 - 12466.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. A. M. Smith, H.-W. Tsui, E. W. Newell, X. Jiang, X.-P. Zhu, F. W. L. Tsui, and L. C. Schlichter
Functional Up-regulation of HERG K+ Channels in Neoplastic Hematopoietic Cells
J. Biol. Chem., May 17, 2002; 277(21): 18528 - 18534.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics